Amyloidosis and the Kidney: An Update

Area of Science:

• Nephrology
• Hematology
• Immunology

Background:

• Systemic amyloidosis poses a significant threat to kidney architecture and function.
• Suspect amyloidosis in patients with declining kidney function, proteinuria, or multisystem disease, though isolated kidney involvement occurs.
• Accurate diagnosis of amyloidosis type and organ dysfunction is vital for effective treatment selection and improved survival.

Purpose of the Study:

• To emphasize the importance of diagnosing and staging systemic amyloidosis, particularly light chain amyloidosis, for guiding renal disease management.
• To highlight the role of biomarkers in assessing disease progression and treatment response.
• To underscore the significance of a multidisciplinary approach in managing complex amyloidosis cases.

Main Methods:

• Clinical suspicion based on renal dysfunction and proteinuria.
• Diagnostic confirmation of amyloidosis type and extent of organ involvement.
• Utilizing amyloid renal staging and biomarker-based systems for prognosis and treatment guidance.

Main Results:

• Amyloidosis can present with varying degrees of kidney involvement, from isolated to part of multisystem disease.
• Renal staging in light chain amyloidosis predicts prognosis and risk of end-stage kidney disease.
• Biomarker assessments facilitate therapeutic strategy adjustments and identification of treatment resistance.

Conclusions:

• Prompt diagnosis and typing of amyloidosis are critical for optimizing treatment and patient survival.
• Staging systems and biomarkers are essential tools for managing renal amyloidosis and guiding therapy.
• A collaborative, multidisciplinary team approach is recommended for comprehensive patient care in amyloidosis.